BCL2L1 and plasma cell myeloma: In order to establish an overview of the expression of BCL-xL in various hematological malignancies, a bioinformatic analysis of expression was performed in various types of hematological malignancies, among which NHL subtypes DLBCL, FL, chronic lymphocytic leukemia, and multiple myeloma stand out.